What is Influvac Tetra used for?

Influvac Tetra

Active Ingredient:: B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202
Origin:: EU

Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

influenza vaccine, inactivated, quadrivalent, the active ingredient in Influvac Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It helps prevent influenza caused by the virus strains included in the vaccine in individuals six months of age and older.

GNH India supplies Influvac Tetra as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Healthcare Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Influvac Tetra is an inactivated quadrivalent influenza vaccine that provides protection against seasonal influenza viruses.

Seasonal influenza prevention: induces immunity to the four influenza virus strains contained in the vaccine, reducing the risk of infection.
Influenza prophylaxis in adults: helps lower the incidence of laboratory‑confirmed influenza in people aged 18 years and older.
Influenza prophylaxis in children: offers protection for children from six months of age, decreasing illness severity and complications.

How It Works

Influvac Tetra contains purified, inactivated whole‑virus particles from two influenza A subtypes and two influenza B lineages. After intramuscular or subcutaneous injection, the viral hemagglutinin and neuraminidase antigens are taken up by antigen‑presenting cells, prompting a humoral immune response that generates strain‑specific antibodies. These antibodies neutralize the corresponding influenza viruses, providing active immunity for the upcoming flu season.

Side Effects

Common and serious adverse reactions may occur after administration of Influvac Tetra.

Common Side Effects

Injection site pain: mild to moderate soreness at the injection site.
Redness or swelling: localized erythema or edema around the injection area.
Low‑grade fever: transient temperature rise up to 38 °C.
Headache or myalgia: mild headache or muscle aches lasting 1–2 days.

Serious or Rare Side Effects

Anaphylaxis: severe allergic reaction requiring immediate medical attention.
Guillain‑Barré syndrome: rare neurological disorder that may develop within weeks after vaccination.
Seizures: infrequent occurrence, particularly in children with a history of febrile seizures.

Precautions & Warnings

Before administering Influvac Tetra, consider the following precautions.

Allergic history: avoid use in individuals with known severe allergy to any vaccine component.
Previous reaction: defer vaccination in persons who experienced a serious adverse event after a prior influenza vaccine.
Acute illness: postpone vaccination until recovery from moderate or severe febrile illness.
Age restrictions: ensure the recipient is at least six months old; dosing differs for specific age groups.
Immunocompromised status: vaccine may be less immunogenic; assess benefit‑risk in severely immunosuppressed patients.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Influvac Tetra may interact with other agents, influencing safety or effectiveness.

Major Interactions (Avoid)

Live viral vaccines: avoid co‑administration within 4 weeks due to potential interference with immune response.
Immunoglobulin therapy: concurrent use may reduce vaccine‑induced antibody production.

Moderate Interactions (Monitor Closely)

Antipyretics: prophylactic use may blunt the antibody response; consider timing after vaccination.
Anticoagulants: intramuscular injection may increase bleeding risk; apply pressure post‑injection.
Immunosuppressive drugs: may diminish immunogenicity; monitor serologic response if needed.

Frequently Asked Questions

Influvac Tetra is an inactivated quadrivalent influenza vaccine indicated for the prevention of seasonal influenza caused by the four virus strains included in the formulation. It is administered to individuals six months of age and older to reduce the risk of infection, illness severity, and related complications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 09 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.